Agenus Inc. (NASDAQ:AGEN) Receives $14.50 Consensus PT from Analysts

Agenus Inc. (NASDAQ:AGEN) has been given an average recommendation of “Hold” by the five research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $14.50.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th.

Agenus Stock Performance

NASDAQ AGEN opened at $3.20 on Monday. The firm’s fifty day moving average is $3.27 and its two-hundred day moving average is $3.85. Agenus has a one year low of $1.38 and a one year high of $7.34. The firm has a market cap of $108.83 million, a PE ratio of -1.50 and a beta of 1.57.

Institutional Investors Weigh In On Agenus

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its position in Agenus by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock valued at $9,893,000 after buying an additional 36,983 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Agenus by 721.1% in the 4th quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after acquiring an additional 477,346 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after acquiring an additional 427,604 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Agenus during the second quarter worth about $1,976,000. Finally, Bank of America Corp DE increased its stake in shares of Agenus by 110.0% during the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after acquiring an additional 220,327 shares during the period. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.